Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Biol Psychiatry. 2013 Oct 16;76(1):47–56. doi: 10.1016/j.biopsych.2013.09.034

Figure 8.

Figure 8

Co-treatment with valproic acid (VPA) blocked METH-induced increased enrichment of HDAC2 on (A) GluA1 and (B) GluA2 gene promoters. VPA also blocked decreased enrichment of H4K16ac on (C) GluA1 but not on (D) GluA2 gene promoters. Sodium valproate (300 mg/kg) was injected intraperitoneally twice a day 30 min prior to either saline or to METH injections. Drug administration and ChIP-PCR for GluA1 and GluA2 are as described in the text. ChIP assays (n=4 – 6 rats per group) were carried out using an antibody against HDAC2 and H4K16ac. Values for all experiments represent means ± SEM of fold changes relative to the controls. Statistics are as described in Figure 7. Key to statistics: * p< 0.05 (Bonferroni).